LABCORP HOLDINGS INC. (LH): what the price assumes

In the published model solve dated 2026-Q2, anchored at $335.11, LABCORP HOLDINGS INC. (LH) is priced for +6.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/LH

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.4% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.6%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Labcorp runs two businesses: a vast clinical-diagnostics lab network and a biopharma laboratory-services arm that supports drug-developer trials, giving it both steady testing volume and exposure to pharma research spending.
• Growth is steady rather than spectacular, revenue up about 6% in the most recent quarter, and the price embeds only modest expectations, which makes execution and margin the swing factors rather than a high-growth story.
• The balance sheet carries meaningful debt, around 4.5 times operating income, much of it from acquisitions, so capital allocation and the integration of acquired labs are key things to watch.

Bull Case

Where the price lands against the methods is the quiet strength of the Labcorp case. The relative-multiple lens against the diagnostics cohort sits close to the current price, and the forward-growth methods reach it as well, while the price itself embeds barely any growth, an implied operating-profit path of roughly flat to slightly negative. That combination, a stock that needs almost nothing to go right to justify its price, is the setup value investors look for in a steady, essential business. Labcorp does not have to grow fast to be worth the quote; it has to keep doing what it does.

What it does is run two complementary engines. The diagnostics business is the steady base: it processes an enormous volume of routine and specialized clinical tests, with the scale that lets it win national contracts and absorb fixed lab costs across millions of samples. The biopharma laboratory-services arm is the higher-growth piece, supporting drug developers' clinical trials, which grew faster in the recent quarter and ties Labcorp to pharma research spending rather than just patient volume. In the most recent quarter diagnostics revenue grew 5.0% to $2.76 billion and biopharma grew 8.2% to $780.6 million, both at mid-teens adjusted margins.

The execution is improving and the capital return is real. Adjusted operating margin expanded to 14.4% from 14.0%, free cash flow turned positive versus a negative figure a year earlier, and the company raised full-year guidance. The share count has fallen about 3% a year, so a steadily growing business is spread across fewer shares. A scaled, essential diagnostics franchise with a faster-growing biopharma arm, improving margins, and a falling share count, priced for almost no growth, is the durable-value bet the bull is making.

Bear Case

The threat to Labcorp is that the testing it does is being pulled in two directions at once, and the price does not fully reflect the squeeze. On one side, hospital and health-system labs are taking volume back: Labcorp's own filing notes that "an increasing number of health system laboratories have expanded their operations and business, resulting in greater competition for testing from physicians within those systems". On the other, specialized molecular and genomic-testing players are competing for the higher-value tests that carry the best margins. The big independent lab model is caught between integrated health systems insourcing routine work and nimble specialists taking the premium work, and that is a slow erosion of the franchise the bull treats as stable.

Reimbursement is the second, structural pressure. Labcorp's revenue depends on what payors and government programs pay per test, and the company flags the shift toward "value-based, bundled pay-for-performance, and other risk-sharing payment models" along with the consolidation of managed-care organizations as challenges. Lab reimbursement has faced years of rate pressure, and a high-volume, fee-per-test business has limited ability to push back when a few large payors set the price. The implied near-flat growth in the price is partly the market already pricing this drift; the bear case is that it could be worse than flat if insourcing and reimbursement cuts accelerate together.

The balance sheet is where the modest growth becomes a constraint. Net debt sits at about 4.5 times operating income, a meaningful load built up largely through acquisitions, with interest covered around six times. That is serviceable for a stable cash generator, but it limits flexibility: a business growing only mid-single digits with this much debt has less room to absorb a reimbursement shock or a volume loss to health-system labs. The valuation is not demanding, which caps the downside somewhat, but the combination of competitive erosion, reimbursement pressure, and acquisition leverage means the steady-compounder story has more fragility than the low multiple implies.

Valuation

The price is making an undemanding bet on Labcorp. At today's quote the shares trade around 19 times company-wide operating income, and inverted, that price implies operating profit growing at roughly minus 1% a year, essentially flat to slightly declining. The market is not paying for growth here; it is paying for a steady, essential business to hold its ground. That framing matters, because it means the bear case is not an overvaluation argument but a question of whether the diagnostics franchise can avoid the slow erosion the low embedded growth already half-anticipates.

The methods split between the value-supportive and the cautious. The relative-multiple lens against the diagnostics cohort lands close to the price, and the forward-growth methods reach it, both supporting the valuation given the modest growth required. The asset-value and earnings-power methods sit below the price, reflecting the heavy intangibles from acquisitions and a current operating margin in the low double digits. The pattern is a within-range name where the relative and growth methods justify the price and the conservative methods say it is full; the spread is not a wide overvaluation gap, it is the normal tension for a steady healthcare compounder. Because the price embeds so little growth, the durability of the diagnostics volume and the biopharma arm, rather than any acceleration, is what defends the multiple.

Solvency is the part that warrants the most attention. Net debt sits at about 4.5 times operating income, with interest covered around six times, a load built up largely through acquisitions. That is manageable for a business with Labcorp's cash generation, but it is real leverage on a company growing only mid-single digits, and it limits the cushion against a reimbursement cut or volume loss to health-system labs. The share count is falling about 3% a year, supporting the equity. The genuine downside variable is the combination of that leverage with competitive and reimbursement pressure; the price already assumes near-flat growth, so the question is whether the business holds that line or slips below it.

Catalysts

The first quarter of 2026 was a steady beat with raised guidance. Revenue rose 5.8% to $3.54 billion, with diluted earnings per share of $3.35, up from $2.52 a year earlier, and adjusted earnings per share up 10.6% to $4.25. Both segments contributed: diagnostics grew 5.0% to $2.76 billion at a 16.6% adjusted margin, and biopharma laboratory services grew 8.2% to $780.6 million at a 15.5% adjusted margin.

Profitability and cash flow improved. Adjusted operating margin expanded to 14.4% from 14.0%, operating cash flow rose to $191.5 million, and free cash flow turned positive at $70.5 million against a negative figure a year earlier. On the strength of the quarter, Labcorp raised full-year enterprise revenue guidance to $14.65 to $14.80 billion and lifted its adjusted earnings outlook to $17.70 to $18.35.

The near-term watch items are diagnostics test volume against the competitive pressure from health-system and specialty labs, the trajectory of biopharma services as it tracks pharma research spending, and the company's continued lab acquisitions and their integration. Reimbursement developments are the external signal to monitor, since payor rates set the revenue per test that the diagnostics base depends on.

Peer Cohorts (Per Segment, With Filing Citations)

Diagnostics Laboratories (Dx) (reported)

• DGX (QUEST DIAGNOSTICS INC)
• FY2025 10-K: …called "Medicare Advantage" programs. There has been growth of health insurance providers offering Medicare Advantage programs and of beneficiary enrollment in these programs. States also have mandated that Medicaid beneficiaries enroll in private managed care arrangements. We also provide additional services to and…
• FY2025 10-K: …dgx:DiagnosticInformationServicesBusinessMember 2024-01-01 2024-12-31 0001022079 dgx:PhysicianLabServicesMember dgx:DiagnosticInformationServicesBusinessMember 2023-01-01 2023-12-31 0001022079 dgx:HospitalLabServicesMember dgx:DiagnosticInformationServicesBusinessMember 2025-01-01 2025-12-31 0001022079…
• NTRA (NATERA, INC.)
• FY2025 10-K: …our competitors. We rely on internal and third-party data centers and platforms to host our laboratory and cloud-based software, and any interruptions of service or failures may impair our operations and harm our business. We currently maintain a data center at our laboratory facilities in San Carlos, California. In…
• FY2025 10-K: …algorithms and therefore be unable to process tests or conduct any other activities that require access to such algorithms. These types of problems may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks, fraud, spikes in customer usage and denial…
• GH (GUARDANT HEALTH, INC.)
• FY2025 10-K: …to increase market acceptance and sales of our tests, which could prevent us from increasing our revenue or achieving profitability and could cause our stock price to decline. In addition to developing kits, certain diagnostic companies also provide next-generation sequencing platforms that could be used for liquid…
• FY2025 10-K: …tissue include most if not all of the competitors within the liquid biopsy space for therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers are also developing their own tests…
• RDNT (RadNet, Inc.)
• FY2025 10-K: …is expected to reach 84 million, or 23% of the total population by 2054. Because diagnostic imaging use tends to increase as a person ages, we believe the aging population will generate more demand for diagnostic imaging procedures . Greater Consumer Awareness of and Demand for Preventive Diagnostic Screening.…
• FY2025 10-K: …Service. Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Digital Health. For further financial information about these segments, see Note 5, Segment Reporting, in the notes accompanying our consolidated financial statements included in this report.…
• IDXX (IDEXX LABORATORIES INC /DE)
• FY2025 10-K: , and Livestock, Poultry and Dairy. Our Other operating segment combines and presents our human medical diagnostic products business with our out-licensing arrangement because they do not meet the quantitative or qualitative thresholds for reportable segments. Companion Animal Group ("CAG") - Diagnostic and…
• FY2025 10-K: …training, and superior sales and customer service. Our success depends, in part, on our ability to differentiate our products in a way that justifies a premium price. Recurring Diagnostic Revenue . Revenues from our IDEXX VetLab consumable products, our SNAP rapid assay test kits, outside reference laboratory and…

Biopharma Laboratory Services (BLS) (reported)

• IQV (IQVIA HOLDINGS INC.)
• FY2025 10-K: …liable for claims with respect to the actions of third-party investigators, which may adversely affect our financial condition, results of operations and reputation. Social media platforms are increasingly being used to communicate about biopharmaceutical products and the diseases our customers' medicines and drug…
• FY2025 10-K: …or therapeutic concentration. • Our relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use our services. • There is a risk that we may initiate a clinical trial for a client, and then the client becomes…
• ICLR (ICON plc)
• FY2025 20-F: …both traditional and emerging clinical research markets gives global CROs a competitive advantage. Progress within the biotechnology sector The nature of the drugs being developed is continuing to change. Biotechnology is enabling the development of targeted drugs with diagnostic tests to determine whether a drug…
• FY2025 20-F: …Ltda. Brazil 100% RPS do Brasil Serviços de Pesquisas Ltda. Brazil 100% RPS China Inc. British Virgin Islands 100% ICON Clinical Research EOOD Bulgaria 100% KCR CRO Ltd. Bulgaria 100% Pharmaceutical Research Associates Bulgaria EOOD Bulgaria 100% 3065613 Nova Scotia Company Canada 100% ICON Clinical Research (Canada)…
• MEDP (Medpace Holdings, Inc.)
• FY2025 10-K: …or take other actions that would reduce the confidence of our customers in the CRO industry. As a result, the willingness of biopharmaceutical companies to outsource R&D services to CROs could diminish and our business could thus be harmed materially by events outside our control. Other Legal, Regulatory, Insurance…
• FY2025 10-K: …on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small and mid-sized biopharmaceutical companies…
• CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.)
• FY2025 10-K: DL™) offerings, where we provide vivarium space to our clients. Some research institutions prefer to retain certain elements of their research in-house, while outsourcing staffing and management, thus driving demand for our services. We believe that our expertise in early-stage drug research, and in particular…
• FY2025 10-K: …("CDMO") business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies. In 2025, Manufacturing accounted for 19.1% of our total revenue and approximately 2,600 of our employees, including approximately 350 science professionals with advanced degrees. Research…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.